Trial Profile

A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interleukin-2 (Primary) ; KP 1237 (Primary) ; Lymphokine-activated killer cells (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man
Sponsors Biohaven Labs; Biohaven Pharmaceuticals

20 Jan 2025 Status changed from recruiting to completed.
11 Oct 2024 Planned End Date changed from 1 Oct 2026 to 1 Dec 2024.
11 Oct 2024 Planned primary completion date changed from 1 Oct 2025 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com